Gang Zeng

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Coronavirus Disease

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Wanqi Yang, González Pa, Qianqian Xin, Mari Rose De Los Reyes, Ralph Elvi Villalobos, Charissa Fay Corazon Borja-Tabora, Nancy Nazaire Bermal, Alexis M Kalergis, Dan Yu, Wenbin Wu, Susan M Bueno, Liqun Huo, Mario Calvo, null Qinf Study Group, Gang Zeng, Jing Li
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial. Vaccines 12 (8) (2024)
Qianqian Xin, Kaiqin Wang, Teck-Hock Toh, Yue Yuan, Xing Meng, Zhiwei Jiang, Hengming Zhang, Jinye Yang, Huijie Yang, Gang Zeng
Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. Nature communications 15 (1) (2024)
Qianqian Xin, Kaiqin Wang, Teck-Hock Toh, Yue Yuan, Xing Meng, Zhiwei Jiang, Hengming Zhang, Jinye Yang, Huijie Yang, Gang Zeng
Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. Nature communications 15 (1) (2024)
Qianqian Xin, Kaiqin Wang, Teck-Hock Toh, Yue Yuan, Xing Meng, Zhiwei Jiang, Hengming Zhang, Jinye Yang, Huijie Yang, Gang Zeng
Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. Nature communications 15 (1) (2024)